Gastric metastases from primary renal cell carcinoma (RCC) are rare and poorly documented in the existing literature. This case report presents the clinical course of a 65-year-old male with multi-metastatic clear cell RCC (ccRCC) who was incidentally found to have stomach metastases during follow-up magnetic resonance imaging (MRI). Gastric metastases from ccRCC are typically associated with other metastatic sites. They often emerge at an advanced stage of the disease, indicating a poor prognosis. It is therefore important to consider gastric metastases as a potential site of involvement in RCC patients. MRI revealed three gastric mucosal lesions exhibiting hypervascularity, a characteristic feature of ccRCC. Histological analysis confirmed the presence of malignant cells compatible with RCC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504865 | PMC |
| http://dx.doi.org/10.7759/cureus.43637 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Emerging Trends in the Management of Gastric Malignancy with Peritoneal Dissemination: Same Disease, Heterogeneous Prognosis.
Cancers (Basel)
January 2025
First Propaedeutic Department of Surgery, National and Kapodistrian University of Athens, Hippocration General Hospital, 11527 Athens, Greece.
Gastric cancer is a significant global contributor to cancer-related mortality. Stage IV gastric cancer represents a significant percentage of patients in Western countries, with peritoneal dissemination being the most prevalent site. Peritoneal disease comprises two distinct entities, macroscopic (P1) and microscopic (P0CY1), which are associated with poor long-term survival rates.
View Article and Find Full Text PDFEvolution in the Surgical Management of Gastric Cancer Peritoneal Metastases.
Cancers (Basel)
December 2024
Department of Surgery, Division of Surgical Oncology, NYU Langone Health, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA.
Despite therapeutic treatments and the growing utilization of multimodal therapies, gastric cancer (GC) remains a highly aggressive malignancy with high mortality worldwide. Much of the complexity in treating GC is due to the high incidence of peritoneal metastasis (PM), with mean overall survival typically ranging from 4 to 10 months. With current systemic therapy, targeted therapies, and immunotherapies continuing to remain ineffective for GC/PM, there has been a significant growing interest in intraperitoneal (IP) therapies for the treatment of GC/PM.
View Article and Find Full Text PDF[Analysis of the efficacy and influencing factors of immunotherapy in gastric cancer liver metastasic patients].
Zhonghua Wai Ke Za Zhi
January 2025
Department of General Surgery, First Medical Center, Chinese People's Liberation Army General Hospital, Beijing100853, China.
To explore the efficacy and factors affecting the treatment of gastric cancer liver metastasis (GCLM) with immune checkpoint inhibitors (ICI). This is a retrospective cohort study. Clinical and pathological data of 588 patients with GCLM treated at the Department of General Surgery, First Medical Center, People's Liberation Army General Hospital, from January 2018 to December 2022 were retrospectively collected.
View Article and Find Full Text PDFGender differences in systemic inflammatory and nutritional index following radical surgery for advanced gastric cancer.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
August 2024
Department of Gastrointestinal Surgery, General Surgery, Xiangya Hospital, Central South University, Changsha 410008.
Objectives: Albumin-globulin ratio (AGR), prognostic nutritional index (PNI), and platelet-to-lymphocyte ratio (PLR) have been validated as prognostic factors for gastric cancer (GC). However, significant gender differences exist in albumin levels and inflammatory cell counts, and further research is required to understand how these differences influence GC prognosis. This study aims to investigate the prognostic impact of nutritional and inflammatory indicators on GC patients undergoing radical surgery, as well as the influence of gender on these indicators' prognostic value.
View Article and Find Full Text PDFMetastatic pancreatic cancer now in remission: a case report and literature review.
Discov Oncol
January 2025
Hematology Oncology Associates of CNY, Syracuse, USA.
Pancreatic cancer is a highly aggressive malignancy with the majority of patients presenting at a late stage with unresectable or metastatic disease. Even with first line treatment, median survival is approximately 11 months in patients with advanced PDAC. This report details the unique case of a patient that presented with peritoneal metastases from an adenocarcinoma of the body of the pancreas, had a remarkable response to palliative chemotherapy and is alive without evidence of disease 12 months following cessation of all active treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!